BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Anxiety and PTSD clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for anxiety disorders: 86 (70 sponsors; 17 newly posted in the last 180 days, 3 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 13.4, rank 51 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 2, Phase 2 14, Phase 3 13, Phase 4 2, N/A 54.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. new entrant | 3 | P3 3 | 3 | 0 |
| Intra-Cellular Therapies, Inc. | 4 | P2 2, P3 2 | 2 | 1 |
| Beijing Union Pharmaceutical Factory Ltd | 3 | P3 2, P1 1 | 0 | 0 |
| Definium Therapeutics US, Inc. DFTX | 2 | P3 2 | 0 | 0 |
| Psicofarma, S.A. De C.V. | 1 | P3 1 | 0 | 0 |
| Senseye, Inc. | 1 | P3 1 | 0 | 0 |
| Sichuan Jishengtang Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Vanda Pharmaceuticals VNDA | 1 | P3 1 | 0 | 1 |
| Deliberate Solutions Inc. | 3 | NA 3 | 0 | 1 |
| HabitAware Inc. | 2 | NA 2 | 0 | 1 |
| Myota GmbH | 2 | NA 2 | 0 | 0 |
| Power Life Sciences Inc. | 2 | NA 2 | 0 | 0 |
| Psyrin Inc. | 2 | NA 2 | 0 | 0 |
| Reunion Neuroscience Inc | 2 | P2 2 | 0 | 1 |
| Seaport Therapeutics SPTX | 2 | P2 2 | 0 | 2 |
| 7 Generation Games | 1 | EARLY_P1 1 | 0 | 0 |
| A Thousand Colibris, S.L | 1 | NA 1 | 0 | 0 |
| AbbVie ABBV | 1 | P2 1 | 0 | 0 |
| Accexible | 1 | NA 1 | 0 | 0 |
| Afasci Inc | 1 | P2 1 | 0 | 0 |
| Appa Health | 1 | NA 1 | 0 | 0 |
| AppliedVR Inc. | 1 | NA 1 | 0 | 0 |
| Attune Neurosciences Inc new entrant | 1 | NA 1 | 1 | 0 |
| Beneo-Institute | 1 | NA 1 | 0 | 0 |
| Biomedical Discoveries and Neuroscientific Foundations LLC | 1 | NA 1 | 0 | 0 |
New-entrant sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc., Attune Neurosciences Inc.
Recently stopped trials
- NCT07329673 Qbtech AB - suspended: Enrollment/study activities have been temporarily suspended while the sponsor evaluates internal study priorities and resource allocation. T An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
- NCT06483789 HB BioTech, LLC - terminated: Decision to terminate study due to a lack of efficacy in this study population. There were no safety concerns identified that contributed to Efficacy and Safety of HB-1 for Panic Disorder
- NCT07714889 Toivoa Inc - withdrawn: This study does not meet the clinical trial definition under FDAAA 801 / NIH policy - participants aren't prospectively assigned to an inter Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Vanda Pharmaceuticals VNDA | NCT07221578 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Social Anxiety Disorder (SAD) | active not recruiting | 500 |
| 2027-01 est. | P2 | Newleos Therapeutics, Inc. | NCT07323784 A Study of NTX-1472 in Social Anxiety Disorder | Social Anxiety Disorder (SAD) | recruiting | 100 |
| 2027-01 est. | P2 | Synendos Therapeutics AG | NCT07478744 A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder | Generalized Anxiety Disorder | recruiting | 24 |
| 2027-02 est. | P2 | RDC Clinical Pty Ltd | NCT07315516 Sleep and Stress Study | Sleep Disorder (Disorder); Stress; Anxiety | recruiting | 240 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | AbbVie ABBV | NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anx | Generalized Anxiety Disorder (GAD) | recruiting | 315 |
| 2026-10 est. | P3 | Senseye, Inc. | NCT07280065 REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool | PTSD - Post Traumatic Stress Disorder | recruiting | 1900 |
| 2026-08-13 | P3 | Definium Therapeutics US, Inc. DFTX | NCT06809595 A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Generalized Anxiety Disorder | active not recruiting | 245 |
| 2026-07-31 est. | P2 | Oui Therapeutics, Inc. | NCT07316088 Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms | PTSD; Post Traumatic Stress Disorder | active not recruiting | 40 |
| 2026-07-15 | P3 | Definium Therapeutics US, Inc. DFTX | NCT06741228 A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) | Generalized Anxiety Disorder | active not recruiting | 214 |
| 2026-06-30 est. | P3 | Beijing Union Pharmaceutical Factory Ltd | NCT06243640 Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD | Generalized Anxiety Disorder | recruiting | 504 |
| 2026-06-30 est. | P3 | Beijing Union Pharmaceutical Factory Ltd | NCT06243614 Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD | Generalized Anxiety Disorder | recruiting | 410 |
| 2026-06-14 | P2 | Reconnect Labs | NCT06685965 A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances | Posttraumatic Stress Disorder (PTSD); Sleep Disturbances and Insomnia | completed | 12 |
| 2026-06-12 | P2 | VistaGen Therapeutics, Inc. VTGN | NCT06809179 A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With S | Social Anxiety Disorder | completed | 61 |
| 2026-05-25 | P2 | Ono Pharmaceutical Co., Ltd. | NCT06805565 A Study of ONO-1110 in Patients With Social Anxiety Disorder | Social Anxiety Disorder (SAD) | completed | 115 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "anxiety disorders"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.